Orchestra BioMed Holdings (OBIO) Accumulated Expenses (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Accumulated Expenses for 7 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 15.81% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 15.81% YoY), while the FY2025 annual figure was $4.2 million, up 59.26% from the prior year.
• Accumulated Expenses retreated to $1.2 million in Q1 2026 per OBIO's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.0 million in Q3 2024 and bottomed at $202931.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $3.2 million across 5 years, with a median of $2.7 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 17425.26% — and 2025, when it tumbled 71.84%.
• Orchestra BioMed Holdings' Accumulated Expenses stood at $2.5 million in 2022, then gained by 7.3% to $2.7 million in 2023, then retreated by 1.84% to $2.6 million in 2024, then jumped by 59.26% to $4.2 million in 2025, then sank by 72.36% to $1.2 million in 2026.
• Business Quant data shows OBIO's Accumulated Expenses at $1.2 million in Q1 2026, $4.2 million in Q4 2025, and $6.8 million in Q3 2025.